Inbox Robot: Hematology News http://www.inboxrobot.com/news/hematology Constantly updated news and information about a variety of topics. Spectrum Pharmaceuticals Announces Zevalin sBLA Granted Priority Review by the FDA; Target Decision (PDUFA) Date of April 2, 2009 http://www.inboxrobot.com/news.php?fid=201404339 2 Dec 2008 17:31 GMT ... first time in one oral and three poster presentations at the American Society of Hematology (ASH) conference in December 2007. The full publication can be downloaded ahead of print ... EGFR Inhibitors Could Be Effective in Obese Breast Cancer Patients http://www.inboxrobot.com/news.php?fid=201391973 2 Dec 2008 16:48 GMT ... of the breast tissue is made of adipocytes, says Dipali Sharma, Ph.D., professor of oncology/hematology. There is an increasing amount of evidence for the importance of the environment surrounding ... METHODS OF IMMUNE OR HEMATOLOGICAL ENHANCEMENT, INHIBITING TUMOUR FORMATION OR GROWTH, AND TREATING OR PREVENTING CANCER, CANCER SYMPTOMS, OR... http://www.inboxrobot.com/news.php?fid=201381705 2 Dec 2008 15:35 GMT ... METHODS OF IMMUNE OR HEMATOLOGICAL ENHANCEMENT, INHIBITING TUMOUR FORMATION OR GROWTH, AND TREATING OR PREVENTING CANCER, CANCER SYMPTOMS, OR... ... New Program Offers Breast Cancer Clinicians and Patients Support for Pre-Operative Clinical Assessment and Ongoing Surve http://www.inboxrobot.com/news.php?fid=201380878 2 Dec 2008 15:34 GMT ... include direct case management services; the National Hispanic/Latino, African American and Senior Outreach initiatives; Hematologic Cancer Education Program; ACS/PAF Partnership Program and the national Lance Armstrong Foundation Livestrong SurvivorCare ... Eisai Will Initiate First Head-to-Head Study Comparing Dacogen (decitabine for injection) and Vidaza (azacitidine) in Patients with Myelodysplastic Syndromes http://www.inboxrobot.com/news.php?fid=201379725 2 Dec 2008 15:29 GMT ... Dacogen(R) for patients with MDS. To advance the understanding of optimal treatment for MDS, hematological malignancies and other cancers, there are currently more than 30 ongoing trials with Dacogen(R) ... Curbing Hormones' Effects In Obese Patients Could Aid Against Breast Cancer http://www.inboxrobot.com/news.php?fid=201378974 2 Dec 2008 15:28 GMT ... far as breast cancer goes," says senior author Dipali Sharma, PhD, assistant professor of oncology/hematology at Emory University School of Medicine and Emory Winship Cancer Institute. Sharma and her ... New Program Offers Breast Cancer Clinicians and Patients Support for Pre-Operative Clinical Assessment and Ongoing Surveillance of Lymphedema http://www.inboxrobot.com/news.php?fid=201378700 2 Dec 2008 15:27 GMT ... include direct case management services; the National Hispanic/Latino, African American and Senior Outreach initiatives; Hematologic Cancer Education Program; ACS/PAF Partnership Program and the national Lance Armstrong Foundation Livestrong SurvivorCare ... TargeGen Affiliates Scheduled for Oral Presentation of Interim Clinical Trial Data at 2008 ASH Meeting in San Francisco for TG101348, a Potent, Selective, Oral JAK2 Inhibitor in Myeloproliferative Disease Patients http://www.inboxrobot.com/news.php?fid=201374982 2 Dec 2008 15:16 GMT ... TG101348 in myeloproliferative disease patients has been scheduled at the 2008 American Society of Hematology (ASH) Meeting. Details of the presentation are as follows: Title: A Phase I Study ... Eisai Will Initiate First Head-to-Head Study Comparing Dacogen(R) (decitabine for injection) and Vid http://www.inboxrobot.com/news.php?fid=201374975 2 Dec 2008 15:16 GMT ... Dacogen(R) for patients with MDS. To advance the understanding of optimal treatment for MDS, hematological malignancies and other cancers, there are currently more than 30 ongoing trials with Dacogen(R) ... Daiichi Sankyo, Inc. Announces Three Studies of Oral Factor Xa Inhibitor DU-176b Accepted for the 50th Annual Meeting of http://www.inboxrobot.com/news.php?fid=201374643 2 Dec 2008 14:54 GMT ... Xa Inhibitor DU-176b Accepted for the 50th Annual Meeting of the American Society of Hematology Results from Phase II Trial of DU-176b in Atrial Fibrillation Included in Scientific Program ... Daiichi Sankyo, Inc. Announces Three Studies of Oral Factor Xa Inhibitor DU-176b Accepted for the 50 http://www.inboxrobot.com/news.php?fid=201373143 2 Dec 2008 14:52 GMT ... Xa Inhibitor DU-176b Accepted for the 50th Annual Meeting of the American Society of Hematology Daiichi Sankyo, Inc. Announces Three Studies of Oral Factor Xa Inhibitor DU-176b Accepted for ... Eisai Will Initiate First Head-to-Head Study Comparing Dacogen(R) (decitabine for injection) and Vidaza(R) (azacitidine) http://www.inboxrobot.com/news.php?fid=201372482 2 Dec 2008 14:51 GMT ... Dacogen(R) for patients with MDS. To advance the understanding of optimal treatment for MDS, hematological malignancies and other cancers, there are currently more than 30 ongoing trials with Dacogen(R) ... Daiichi Sankyo, Inc. Announces Three Studies of Oral Factor Xa Inhibitor DU-176b Accepted for the 50th Annual Meeting of the American Society of Hematology http://www.inboxrobot.com/news.php?fid=201371193 2 Dec 2008 14:47 GMT ... Xa Inhibitor DU-176b Accepted for the 50th Annual Meeting of the American Society of Hematology Last update: 9:27 a.m. EST Dec. 2, 2008 EDISON, N.J., Dec 02, 2008 /PRNewswire ... Eisai Will Initiate First Head-to-Head Study Comparing Dacogen(R) (decitabine for injection) and Vidaza(R) (azacitidine) in Patients with Myelodysplastic Syndromes http://www.inboxrobot.com/news.php?fid=201369365 2 Dec 2008 14:31 GMT ... Dacogen(R) for patients with MDS. To advance the understanding of optimal treatment for MDS, hematological malignancies and other cancers, there are currently more than 30 ongoing trials with Dacogen(R) ... Immunomedics to Present At 50th ASH Annual Meeting http://www.inboxrobot.com/news.php?fid=201361229 2 Dec 2008 13:51 GMT ... presentations involving its potential products will be given at the 50th American Society of Hematology (ASH) Annual Meeting, scheduled for December 6 - 9, 2008, in San Francisco, California. ...